STOCK TITAN

Medigus Ltd. American Depositary Share - MDGS STOCK NEWS

Welcome to our dedicated page for Medigus Ltd. American Depositary Share news (Ticker: MDGS), a resource for investors and traders seeking the latest updates and insights on Medigus Ltd. American Depositary Share stock.

Medigus Ltd. (NASDAQ: MDGS) is an innovative medical device company renowned for its groundbreaking endoscopic procedures and devices. The company has developed a comprehensive endoscopic system designed for the intraluminal treatment of Gastroesophageal Reflux Disease (GERD), a prevalent chronic condition in the Western world. The centerpiece of Medigus's offering is the SRS system, which integrates a miniaturized video camera, surgical stapler, and ultrasonic sights for precise alignment into a single, flexible endoscope. This unique system allows gastroenterologists and surgeons to perform endoluminal partial anterior fundoplications, thereby eliminating the need for traditional open or laparoscopic surgery, significantly advancing the clinical management of GERD.

Alongside its flagship SRS system, Medigus also designs and manufactures bespoke endoscopy systems for partner companies, leveraging its proprietary technology to meet diverse clinical needs. This dual focus on innovation in GERD treatment and custom endoscopic solutions underscores Medigus's commitment to advancing medical care through minimally invasive techniques.

Based in Israel, Medigus's recent initiatives include strategic partnerships and collaborations to expand the reach and application of their technologies. The company's financial health is bolstered by these partnerships, alongside a strong pipeline of ongoing projects aimed at enhancing patient outcomes and broadening the scope of endoscopic treatments.

For the latest updates, news, and detailed financial information, stakeholders can contact: Tali Dinar, Chief Financial Officer, at ir@medigus.com, or Michal Efraty, Investor Relations, at michal@efraty.com.

Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) announced that ParaZero Technologies (Nasdaq: PRZO), an aerospace company 18.68% owned by Xylo, has initiated a partnership with a leading Tier 1 defense OEM to adapt its drone safety systems for military and medical missions. ParaZero received an initial order for 50 systems for testing, with plans to develop adaptations for medical delivery systems. Upon successful testing, the customer intends to purchase hundreds more systems for a pilot program. The project aims to enhance medical field mission deliveries in critical and remote areas, with completion expected by the end of 2024. ParaZero's goal is to develop a scalable, cost-effective mass production system for wider deployment, potentially entering defense markets and improving healthcare logistics.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) has announced that Revoltz , 19.9% owned by Charging Robotics, Inc. (OTC: CHEV), is developing a new three-wheel electric cargo bike for European and UK markets. The bike features:

  • Enhanced stability and increased payload capacity
  • Advanced full-tilting suspension system
  • Compliance with European and UK regulatory standards
  • Pedal and electric motor combination for efficient, eco-friendly rides
  • Versatile configurations for various transportation needs

The prototype is expected within three months, with commercialization anticipated for early 2025. This innovative product aims to address urban transportation challenges and promote sustainable mobility solutions.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) has announced a planned reverse split of its American Depositary Receipt (ADR) program. The ratio change will be 1 new ADS for every 2.666666 old ADSs. Each new ADS will represent 40 ordinary shares, up from the previous 15. The effective date is set for August 5, 2024. Xylo's ADSs will continue trading on Nasdaq under the symbol 'XYLO' with a new CUSIP Number. ADS holders must surrender their old ADSs to BNY Mellon for cancellation. The change will not affect the company's ordinary shares or alter shareholders' ownership percentages, except for minor adjustments due to fractional ADSs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.33%
Tags
none
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) announced that its subsidiary, Charging Robotics, Inc. (OTC: CHEV), received its first commercial order for wireless charging systems in automatic parking facilities. The order, from Parking Design , is for 12 systems to be delivered throughout 2025. This follows a pilot project in Tel Aviv, Israel.

Charging Robotics' system uses machine learning and AI to manage EV charging efficiently, prioritizing based on factors like departure time and vehicle type. This technology addresses increasing electricity demand in parking facilities. The collaboration aims to revolutionize EV management and charging in automated parking environments, focusing on sustainability and operational excellence.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.52%
Tags
none
-
Rhea-AI Summary

Xylo Technologies announces that Charging Robotics, a company it owns a 67% stake in, has received its first commercial order for its wireless EV charging systems from Parking Design. This order entails the deployment of 12 systems in automatic parking facilities, to be fulfilled throughout 2025. The wireless charging system uses AI and machine learning to optimize EV charging, ensuring efficient and prioritized energy distribution. This innovation aims to enhance the convenience and sustainability of automated parking solutions. A pilot project was recently completed in Tel Aviv, marking a significant milestone in their collaboration.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
none
-
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) announced that its subsidiary Gix Internet (45.75% owned by Xylo, TASE: GIX) signed a non-binding MOU with a robotics company specializing in AI autonomous robotics for medical logistics. The MOU outlines a share exchange transaction, where the robotics company will become a wholly-owned subsidiary of Gix. The completion of this transaction is expected to provide Gix with growth opportunities and technological advancements in AI and robotics. Shareholders of the robotics company will receive 30% of Gix's ordinary shares, with options to increase holdings to 37.5% and 45% upon meeting specific commercial milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.06%
Tags
Rhea-AI Summary

Xylo Technologies announced that its 19.99% owned subsidiary, Metagramm Software, completed the development of Bubbl, an advanced AI-powered writing tool. Bubbl employs Machine Learning, Natural Language Processing, and Deep Learning to offer personalized text writing and rewriting, setting it apart from other AI tools. The tool features a clean design and various user modes, including interactive re-write and grammar-only modes. It supports multiple writing profiles, such as Business, Medical, Academic, and Blogging, each with tailored assistance. Bubbl will launch for select users in Q3 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
AI
-
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) has signed a letter of intent (LOI) to acquire a leading AI technology company based in Germany. This acquisition aims to expand Xylo's portfolio into advanced AI technologies such as predictive maintenance and condition monitoring. The target company has been a European leader for over a decade, providing AI and machine learning solutions to various global industries including aerospace, aviation, transportation, real estate, and security. Xylo will make a down payment of 1.5 million Euros and initially acquire 51% of the target company's shares, with the remaining 49% contingent on the company's 2024 EBITDA results. This strategic move was facilitated by Xylo's newly appointed senior advisor, an expert in AI with a distinguished career in both academia and industry.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
19.9%
Tags
-
Rhea-AI Summary

Xylo Technologies (Nasdaq: XYLO) announced that Charging Robotics (OTC: FDOCD), 67% owned by Xylo, in collaboration with Make My Day, has reached the final development stage of an AI-based EV charging management system.

This system addresses the challenge of insufficient electricity supply for EV charging in automatic car parks by using machine learning algorithms to prioritize and optimize charging sequences based on parameters such as departure time, vehicle type, and driving style.

The system integrates seamlessly with Charging Robotics’ wireless charging setup and was recently piloted in Tel Aviv, Israel.

CEO Hovav Gilan emphasized the value this feature adds for future customers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.88%
Tags
AI
Rhea-AI Summary
Xylo Technologies, formerly known as Medigus , has filed its 2023 Annual Report on Form 20-F, including audited financial statements for the year ended December 31, 2023. The report is available on the company's investor relations website and the SEC's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none

FAQ

What is the current stock price of Medigus Ltd. American Depositary Share (MDGS)?

The current stock price of Medigus Ltd. American Depositary Share (MDGS) is $2.36 as of June 11, 2024.

What is the market cap of Medigus Ltd. American Depositary Share (MDGS)?

The market cap of Medigus Ltd. American Depositary Share (MDGS) is approximately 4.5M.

What does Medigus Ltd. specialize in?

Medigus Ltd. specializes in innovative endoscopic procedures and devices, particularly for the treatment of GERD.

What is the SRS system?

The SRS system is an endoscopic solution that combines a miniaturized camera, surgical stapler, and ultrasonic sights to treat GERD without open or laparoscopic surgery.

How does the SRS system benefit GERD patients?

The SRS system allows for a minimally invasive procedure, reducing the need for more invasive surgeries and potentially improving recovery times.

Does Medigus Ltd. collaborate with other companies?

Yes, Medigus designs and manufactures endoscopy systems for partner companies using its proprietary technologies.

Where is Medigus Ltd. based?

Medigus Ltd. is based in Israel.

Who can I contact for investor relations at Medigus?

For investor relations, you can contact Michal Efraty at michal@efraty.com.

What is the primary medical condition that Medigus's technology addresses?

Medigus's technology primarily addresses Gastroesophageal Reflux Disease (GERD).

How does the SRS system work?

The SRS system uses a flexible endoscope with a built-in camera, stapler, and ultrasonic guide to perform partial anterior fundoplication endoluminally.

What are the recent initiatives of Medigus Ltd.?

Recent initiatives include strategic partnerships and ongoing projects to enhance their technology's reach and applications.

How can I get the latest news about Medigus Ltd.?

You can get the latest news by contacting their Chief Financial Officer Tali Dinar or Investor Relations Michal Efraty, or visiting their official communications.

Medigus Ltd. American Depositary Share

Nasdaq:MDGS

MDGS Rankings

MDGS Stock Data

4.47M
28.42M
0.29%
0.22%
Medical Devices
Healthcare
Link
United States of America
Tel Aviv